Elanco Animal Health (ELAN) Stock Forecast & Price Target

Compare

393 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ELAN Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Elanco

Animal Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ELAN Stock 12 Month Forecast

Average Price Target

$15.83

▲(11.48% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Elanco Animal Health in the last 3 months. The average price target is $15.83 with a high forecast of $18.00 and a low forecast of $12.00. The average price target represents a 11.48% change from the last price of $14.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","19":"$19","10.75":"$10.75","13.5":"$13.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,10.75,13.5,16.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.43,14.704615384615384,14.97923076923077,15.253846153846153,15.528461538461539,15.803076923076922,16.077692307692306,16.352307692307694,16.626923076923077,16.90153846153846,17.176153846153845,17.450769230769232,17.725384615384616,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.43,14.537692307692307,14.645384615384614,14.753076923076923,14.86076923076923,14.968461538461538,15.076153846153845,15.183846153846154,15.291538461538462,15.399230769230769,15.506923076923076,15.614615384615385,15.722307692307693,{"y":15.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.43,14.243076923076924,14.056153846153846,13.86923076923077,13.682307692307692,13.495384615384616,13.308461538461538,13.121538461538462,12.934615384615384,12.747692307692308,12.56076923076923,12.373846153846154,12.186923076923076,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.1,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.11,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$18.00

Average Price Target$15.83

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$16.5

Buy

16.20%

Upside

Reiterated

07/11/25

Elanco's strong earnings call and strategic CFO appointment boost its overall outlook, despite moderate financial performance and valuation concerns. Technical indicators suggest caution due to potential overbought conditions.

Erin WrightMorgan Stanley

Morgan Stanley

$10→$15

Hold

5.63%

Upside

Reiterated

07/29/25

Morgan Stanley Keeps Their Hold Rating on Elanco Animal Health (ELAN)Morgan Stanley analyst Erin Wright raised the price target on Elanco Animal Health (NYSE: ELAN) to $15.00 (from $10.00) while maintaining a Equalweight rating.

Andrea AlfonsoUBS

UBS

$17→$18

Buy

26.76%

Upside

Reiterated

07/23/25

Elanco price target raised to $18 from $17 at UBSElanco price target raised to $18 from $17 at UBS

Daniel ClarkLeerink Partners

Leerink Partners

$14.5→$18

Buy

26.76%

Upside

Upgraded

07/17/25

Elanco upgraded to Outperform from Market Perform at LeerinkElanco upgraded to Outperform from Market Perform at Leerink

Jonathan BlockStifel Nicolaus

Stifel Nicolaus

$17

Buy

19.72%

Upside

Reiterated

07/07/25

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and uniQure (NASDAQ: QURE)

Brandon VazquezWilliam Blair

William Blair

―

Buy

―

Upgraded

06/26/25

William Blair upgrades Elanco Animal Health (ELAN) to a Buy

Steve ScalaTD Cowen

TD Cowen

$15

Buy

5.63%

Upside

Reiterated

06/24/25

TD Cowen Sticks to Its Buy Rating for Elanco Animal Health (ELAN)

David WestenbergPiper Sandler

Piper Sandler

$12

Hold

-15.49%

Downside

Reiterated

05/12/25

Piper Sandler Reaffirms Their Hold Rating on Elanco Animal Health (ELAN)

Umer RaffatEvercore ISI

Evercore ISI

―

Buy

―

Reiterated

05/12/25

Evercore ISI Remains a Buy on Elanco Animal Health (ELAN)

Michael RyskinBank of America Securities

Bank of America Securities

$13

Buy

-8.45%

Downside

Reiterated

05/07/25

Elanco's Promising Growth and Strong Performance Earns Buy Rating from Michael Ryskin

Glen SantangeloJefferies

Jefferies

$18

Buy

26.76%

Upside

Reiterated

03/03/25

Elanco Animal Health: Undervalued Growth Potential with Strong Product Performance and Debt Reduction

Balaji PrasadBarclays

Barclays

$20

Buy

40.85%

Upside

Reiterated

02/25/25

Barclays Remains a Buy on Elanco Animal Health (ELAN)

Jasper HellwegArgus Research

Argus Research

―

Hold

―

Reiterated

11/21/24

We are reiterating our Hold rating on Elanco Animal Health Inc.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$16.5

Buy

16.20%

Upside

Reiterated

07/11/25

Erin WrightMorgan Stanley

Morgan Stanley

$10→$15

Hold

5.63%

Upside

Reiterated

07/29/25

Andrea AlfonsoUBS

UBS

$17→$18

Buy

26.76%

Upside

Reiterated

07/23/25

Elanco price target raised to $18 from $17 at UBSElanco price target raised to $18 from $17 at UBS

Daniel ClarkLeerink Partners

Leerink Partners

$14.5→$18

Buy

26.76%

Upside

Upgraded

07/17/25

Elanco upgraded to Outperform from Market Perform at LeerinkElanco upgraded to Outperform from Market Perform at Leerink

Jonathan BlockStifel Nicolaus

Stifel Nicolaus

$17

Buy

19.72%

Upside

Reiterated

07/07/25

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and uniQure (NASDAQ: QURE)

Brandon VazquezWilliam Blair

William Blair

―

Buy

―

Upgraded

06/26/25

William Blair upgrades Elanco Animal Health (ELAN) to a Buy

Steve ScalaTD Cowen

TD Cowen

$15

Buy

5.63%

Upside

Reiterated

06/24/25

TD Cowen Sticks to Its Buy Rating for Elanco Animal Health (ELAN)

David WestenbergPiper Sandler

Piper Sandler

$12

Hold

-15.49%

Downside

Reiterated

05/12/25

Piper Sandler Reaffirms Their Hold Rating on Elanco Animal Health (ELAN)

Umer RaffatEvercore ISI

Evercore ISI

―

Buy

―

Reiterated

05/12/25

Evercore ISI Remains a Buy on Elanco Animal Health (ELAN)

Michael RyskinBank of America Securities

Bank of America Securities

$13

Buy

-8.45%

Downside

Reiterated

05/07/25

Elanco's Promising Growth and Strong Performance Earns Buy Rating from Michael Ryskin

Glen SantangeloJefferies

Jefferies

$18

Buy

26.76%

Upside

Reiterated

03/03/25

Elanco Animal Health: Undervalued Growth Potential with Strong Product Performance and Debt Reduction

Balaji PrasadBarclays

Barclays

$20

Buy

40.85%

Upside

Reiterated

02/25/25

Barclays Remains a Buy on Elanco Animal Health (ELAN)

Jasper HellwegArgus Research

Argus Research

―

Hold

―

Reiterated

11/21/24

We are reiterating our Hold rating on Elanco Animal Health Inc.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elanco Animal Health

1 Month

xxx

Success Rate

9/15 ratings generated profit

Average Return

+5.98%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +5.98% per trade.

3 Months

xxx

Success Rate

8/12 ratings generated profit

Average Return

+10.00%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +10.00% per trade.

1 Year

Michael RyskinBank of America Securities

Success Rate

13/20 ratings generated profit

Average Return

+16.38%

reiterated a buy rating 3 months ago

Copying Michael Ryskin's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +16.38% per trade.

2 Years

xxx

Success Rate

9/15 ratings generated profit

Average Return

+7.21%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +7.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELAN Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ELAN has received 18 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. ELAN average Analyst price target in the past 3 months is 15.83.

Each month's total comprises the sum of three months' worth of ratings.

ELAN Financial Forecast

ELAN Earnings Forecast

Next quarter’s earnings estimate for ELAN is $0.13 with a range of $0.12 to $0.16. The previous quarter’s EPS was $0.26. ELAN beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year ELAN has Preformed in-line its overall industry.

ELAN Sales Forecast

Next quarter’s sales forecast for ELAN is $1.09B with a range of $1.07B to $1.10B. The previous quarter’s sales results were $1.24B. ELAN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year ELAN has Preformed in-line its overall industry.

ELAN Stock Forecast FAQ

What is ELAN’s average 12-month price target, according to analysts?

Based on analyst ratings, Elanco Animal Health’s 12-month average price target is 15.83.

What is ELAN’s upside potential, based on the analysts’ average price target?

Elanco Animal Health has 11.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ELAN a Buy, Sell or Hold?

Elanco Animal Health has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is Elanco Animal Health’s price target?

The average price target for Elanco Animal Health is 15.83. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $12.00. The average price target represents 11.48% Increase from the current price of $14.2.

What do analysts say about Elanco Animal Health?

Elanco Animal Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of ELAN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Elanco Animal Health (ELAN) Stock Forecast & Price Target

ELAN Analyst Ratings

ELAN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Elanco Animal Health

ELAN Analyst Recommendation Trends

ELAN Financial Forecast

ELAN Earnings Forecast

ELAN Sales Forecast

ELAN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts